Kadcyla | featured news

FDA approves new targeted breast cancer drug

Roche

The Food and Drug Administration says it has approved a new form of a best-selling breast cancer drug that targets tumor cells while sparing healthy ones. The drug Kadcyla (kad-SY'-luh) from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a double-shot of anti-tumor poison.

 

Subscribe to this RSS topic: Syndicate content